PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

BTG Announces Varithena™ Data Demonstrating Continued Improvement At One Year At The American Venous Forum Annual Meeting - Data show clinically meaningful, ongoing improvements in patients with varicose veins caused by saphenofemoral junction incompetence - BTGplc.com
BTG Announces Varithena™ Data Demonstrating Continued Improvement At One Year At The American Venous Forum Annual Meeting

 

NewswireToday - /newswire/ - London, United Kingdom, 2014/02/21 - Data show clinically meaningful, ongoing improvements in patients with varicose veins caused by saphenofemoral junction incompetence - BTGplc.com. LSE: BTG

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Today at the 26th Annual Meeting of the American Venous Forum in New Orleans, LA, Dr. Kenneth Todd, an American College of Phlebology Committee Member from the Southeast Vein and Laser Center and a Principal Investigator for VANISH-2, presented one-year data from the VANISH-2 clinical trial, one of the two pivotal trials for Varithena™ (polidocanol injectable foam). Varithena™, which was developed by the specialist healthcare company BTG, received US approval from the FDA in November 2013 for the treatment of varicose veins caused by saphenofemoral junction (SFJ) incompetence. Commercial launch in the US is planned in the second quarter of this year.

One-year results from VANISH-2, a study in which patients with symptomatic and visible varicose veins caused by saphenofemoral junction (SFJ) incompetence were treated with Varithena™, indicate that treatment with Varithena™ led to clinically meaningful and ongoing improvements in symptoms, as measured by the VVSymQ® score.

The VVSymQ® electronic daily diary is the first and only patient-reported outcomes instrument that measures the burden of varicose vein symptoms developed in accordance with FDA guidelines. The VVSymQ® score measures the five most relevant symptoms to patients: heaviness, achiness, swelling, throbbing, and itching. VVSymQ® scores range from 0 to 25, where 0 represents no symptoms and 25 represents all 5 symptoms experienced all of the time.

At baseline, 12% of patients treated with Varithena™ 1% reported a VVSymQ® score of 3 or less, whereas 84% of patients reported a VVSymQ® score of 3 or less at Year 1. The mean improvement in VVSymQ® score relative to baseline was 4.7 points at Week 8 and 6.2 points at Year 1.

Continued improvement at Year 1 was also shown in:

Appearance, as measured by a blinded independent panel review of photographs (IPR-V3) and a patient-reported outcome instrument (PA-V3)
Disease severity, as measured by the Venous Clinical Severity Score (VCSS), and
Varicose vein-related quality of life, as measured by the Venous Insufficiency Epidemiological and Economic Study­−Quality of Life (VEINES-QOL) score.

Serious adverse events reported in the long-term follow-up period were typical of those that would be expected of the patient population studied and were unrelated to treatment.

“The one-year data from VANISH-2 are important because they show that clinically meaningful improvements in symptoms and appearance are sustained one year after treatment,” said Dr. Kenneth Todd, MD,“On-going improvements as shown in the VANISH-2 analysis support the recent FDA approval of Varithena™, which offers a new treatment option for patients with varicose veins.”

About Varithena™

Varithena™ (polidocanol injectable foam) is the first and only FDA approved foam for the treatment of incompetent veins and visible varicosities of the great saphenous vein (GSV) system. Varithena™ improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.1

Varithena™ is a low-nitrogen (less than 0.8%) foam with controlled properties for consistent performance. Varithena™ has been studied in over 1,300 patients in 12 clinical trials, including two Phase III placebo-controlled trials, VANISH-1 and VANISH-2.

About BTG

BTG is an international specialist healthcare company that is developing and commercializing products targeting acute care, cancer and vascular diseases. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians. For further information about BTG please visit our website at btgplc.com.

IMPORTANT SAFETY INFORMATION About VARITHENA™
For more complete information about the use of Varithena™, please see the full Prescribing Information available at Varithena.com.

Indications
Varithena™ (polidocanol injectable foam) is a prescription medicine used to treat varicose veins and the associated affected veins in the great saphenous vein (GSV) system. Varithena™ can be used to treat veins above and below the knee. Varithena™ improves varicose vein symptoms and appearance.

IMPORTANT SAFETY INFORMATION FOR PATIENTS

Varithena™ is administered by a doctor and is for intravenous use only in the affected veins. Doctors must be trained in the administration of Varithena™.

You should not receive Varithena™ if:

you have a known allergy to polidocanol,
you have an acute vein or blood clotting disease, or
you are pregnant.

Warnings and Precautions
Because severe allergic reactions, including anaphylactic reactions, have occurred with other forms of polidocanol, patients should be observed for such reactions for at least 10 minutes following injection with Varithena™.

Injection of polidocanol into arteries or into the tissue outside the vein can cause severe necrosis, ischemia, or gangrene. If Varithena™ is injected into an artery, a vascular surgeon should be consulted immediately.

Varithena™ can cause blood clots (venous thrombi). Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization, or pregnancy are at increased risk for developing blood clots.

Drug Interactions
No specific drug interaction studies have been performed. There are no known drug interactions with Varithena™.

Adverse Reactions
In clinical trials, the most common side effects (occurring in 3% or more of patients treated with Varithena™) were leg pain/discomfort, retained coagulum (pocket of blood in the treated vein), injection site hematoma (bruise) or pain, superficial thrombophlebitis (clot in a superficial vein) and extravasation (accidental administration of drug outside the vein).

References:

1. Varithena™ prescribing information. Provensis Ltd, a BTG International group company. November 2013.

Varithena is a trademark of Provensis Ltd., a BTG International group company. VVSymQ, BTG and the BTG roundel logo are registered trademarks of BTG International Ltd.

For further information please contact:

Vox Medica, Courtney Prizer, Account Supervisor, United States
T: 267-322-1181 - E: cprizer[.]voxmedica.com.

Melissa Scherkoske, Senior Vice President, United States
T: 215-817-6399 - E: mscherkoske[.]voxmedica.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocompatibles UK Ltd / BTG Plc

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


BTG Announces Varithena™ Data Demonstrating Continued Improvement At One Year At The American Venous Forum Annual Meeting

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

BTG |
Publisher Contact: Ashley Tapp - BTGplc.com 
+44(0)20 7575 1513 / +44(0)77 9081 1554 (Mobile) ashley.tapp[.]btgplc.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocompatibles UK Ltd / BTG Plc securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocompatibles UK Ltd / BTG Plc / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  JobsWare.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)